Accelerate Diagnostics, Inc.

Good day and welcome to the Accelerate Diagnostics, Inc. 2022 First Quarter Results Conference Call. All participants will be in listen-only mode. After today's presentation, there will be a question and answer session. Please note, this event is being recorded. I would now like to turn the conference over to Laura Pearson of Accelerate Diagnostics. Please go ahead.

Before we begin, it is important to share that information presented during this call may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include projections, statements about our future, and those that are not historical facts. All forward-looking statements that are made during this conference call are subject to risk, uncertainties, and other factors that could cause our actual results to differ materially. These are discussed in greater detail in our annual report on Form 10-K for the year into December 31st, 2021, and other reports we file with the SEC. It is my pleasure to now introduce the company's president and CEO, Jack Phillips.

Thank you, Laura. Good afternoon, everyone, and welcome to our first quarter 2022 earnings call. We were pleased to see improved access to current and prospective customers in the latter part of the first quarter. This positive trend contributed to the achievement of commercial results consistent with our expectations. We also achieved all product development milestones for the quarter. As promised, we launched as an RUO our new rapid multi-sample preparation solution, ARC, prior to the quarter end. and today announced its launch as an IVD ahead of schedule. AHRQ, in its early days of commercialization, has already generated numerous evaluations and inbound interest from potential commercial partners. In addition to AHRQ, we completed enhancements to FINO and locked the design of our FINO II platform. Before providing additional details on our progress during the quarter, I'd like to hand it over to Steve to review our first quarter financial results. Steve. Thank you, Jack.